Abstract

Background. Respiratory syncytial virus (RSV) is one of the most common pathogens causing severe lower respiratory tract disease in infancy and childhood. In newborns, young infants, and in infants with co-morbidities, the risk of severe infection is increased. Current protection against severe RSV infection is immunoprophylaxis with the monoclonal antibody palivizumab. The study aimed to assess the effects of palivizumab prophylaxis in the Republic of Montenegro in comparison to the pre-prophylaxis period.

Methods. The study was conducted in prospective/retrospective single center format in Montenegro in the Clinical Center of Podgorica, for the period 2009-2019.

Results. A total of 104 high-risk infants in the palivizumab prophylaxis program (2014-2019 RSV seasons) and 168 high-risk children without palivizumab prophylaxis (2009-2013 RSV seasons) were enrolled. A total of 51 children (49.0%) received prophylaxis for prematurity, 33 (31.7%) for bronchopulmonary dysplasia (BPD), 13 (12.5%) for hemodynamically significant heart disease/defect (HSCHD), and 7 (6.8%) for “miscellaneous” indications. In the control group most children had prematurity (101, 60.1%), followed by BPD (59, 35.1%), HSCHD (3, 1.8%), and “miscellaneous” (5, 3.4%) conditions. Readmission to the pediatric intensive care units (PICU) due to RSV infection was significantly lower in prophylaxis group (0.0 vs 16.1%, p<0.001). No lethal outcomes were observed in high-risk children with palivizumab prophylaxis compared to 2.4% in the control group.

Conclusions. The introduction of RSV immunoprophylaxis as well as other new protective treatment strategies for high-risk newborns led to significant improvements in infant and childcare in Montenegro. This is the first report on palivizumab prophylaxis in Montenegro, demonstrating the effectiveness and safety of palivizumab use in clinical settings.

Keywords: palivizumab, respiratory syncytial virus (RSV), high-risk children, Montenegro

Supplementary materials
Supplementary Tables

Copyright and license

Copyright © 2024 The Author(s). This is an open access article distributed under the Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Lekic E, Dragas L, Nikcevic D, Lekic J, Dedic A, Sulovic L. Effects of palivizumab prophylaxis on respiratory syncytial virus (RSV) infections in Montenegro. Turk J Pediatr 2024; 66: 161-170. https://doi.org/10.24953/turkjpediatr.2024.4592

References

  1. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus--a comprehensive review. Clin Rev Allergy Immunol 2013; 45: 331-379. https://doi.org/10.1007/s12016-013-8368-9
  2. Liese J, Forster L. S2k-Leitlinie zur Prophylaxe von schweren Erkrankungen durch Respiratory Syncytial Virus (RSV) bei Risikokindern (German guideline on severe RSV infection prophylaxis in children at risk). Update 2017/2018.
  3. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545-1555. https://doi.org/10.1016/S0140-6736(10)60206-1
  4. Mitchell I, Li A, Bjornson CL, Lanctot KL, Paes BA; CARESS Investigators. Respiratory syncytial virus immunoprophylaxis with palivizumab: 12-year observational study of usage and outcomes in Canada. Am J Perinatol 2022; 39: 1668-1677. https://doi.org/10.1055/s-0041-1725146
  5. Higgins D, Trujillo C, Keech C. Advances in RSV vaccine research and development - A global agenda. Vaccine 2016; 34: 2870-2875. https://doi.org/10.1016/j.vaccine.2016.03.109
  6. Verwey C, Dangor Z, Madhi SA. Approaches to the prevention and treatment of respiratory syncytial virus infection in children: rationale and progress to date. Paediatr Drugs 2024; 26: 101-112. https://doi.org/10.1007/s40272-023-00606-6
  7. Resch B. Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection. Hum Vaccin Immunother 2017; 13: 2138-2149. https://doi.org/10.1080/21645515.2017.1337614
  8. Huang K, Incognito L, Cheng X, Ulbrandt ND, Wu H. Respiratory syncytial virus-neutralizing monoclonal antibodies motavizumab and palivizumab inhibit fusion. J Virol 2010; 84: 8132-8140. https://doi.org/10.1128/JVI.02699-09
  9. Simoes EA, Groothuis JR. Respiratory syncytial virus prophylaxis-the story so far. Respir Med 2002; 96(Suppl B): S15-S24. https://doi.org/10.1016/s0954-6111(02)90066-1
  10. UK Health Security Agency. Respiratory syncytial virus: the green book, chapter 27a. 2015. Available at: https://www.gov.uk/government/publications/respiratory-syncytial-virus-the-green-book-chapter-27a
  11. European Foundation for the Care of Newborn Infants (EFCNI). Position paper: Respiratory syncytial virus (RSV) in preterm and ill infants. 2021. Available at: https://www.efcni.org/wp-content/uploads/2023/04/EFCNI_Positionpaper_RSV_EN_web.pdf
  12. Blanken MO, Rovers MM, Molenaar JM, et al. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 2013; 368: 1791-1799. https://doi.org/10.1056/NEJMoa1211917
  13. The IMpact-RSV Study Group. Palivizumab; a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102: 531-537. https://doi.org/10.1542/peds.102.3.531
  14. Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143: 532-540. https://doi.org/10.1067/s0022-3476(03)00454-2
  15. Simon A, Gehrmann S, Wagenpfeil G, Wagenpfeil S. Use of palivizumab in Germany - Report from the German Synagis™ Registry 2009 - 2016. Klin Padiatr 2018; 230: 263-269. https://doi.org/10.1055/a-0595-7771
  16. Baranov AA, Ivanov DO, Aliamovskaia GA, et al. Palivizumab: four seasons in Russia. Vestn Ross Akad Med Nauk 2014; (7-8): 54-68. https://doi.org/10.15690/vramn.v69i7-8.1110
  17. Borecka R, Lauterbach R. Compliance with the RSV immunoprophylaxis dosing schedule in the Polish registry for palivizumab (2008-2014). Dev Period Med 2018; 22: 308-314. https://doi.org/10.34763/devperiodmed.20182204.308314
  18. Heljic S, Maksic H, Begic H, et al. Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina. J Pediatr Neonat Individual Med 2016; 5: e050129. https://doi.org/10.7363/050129
  19. Robinson JL, Le Saux N; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Preventing hospitalizations for respiratory syncytial virus infection. Paediatr Child Health 2015; 20: 321-333. https://doi.org/10.1093/pch/20.6.321
  20. American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 2014; 134: 415-420. https://doi.org/10.1542/peds.2014-1665
  21. Lacaze-Masmonteil T, Rozé JC, Fauroux B; French Pediatricians' Group of Sunagis Patients' Name-Based Programs. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Pediatr Pulmonol 2002; 34: 181-188. https://doi.org/10.1002/ppul.10175
  22. Shi Y, Muniraman H, Biniwale M, Ramanathan R. A Review on non-invasive respiratory support for management of respiratory distress in extremely preterm infants. Front Pediatr 2020; 8: 270. https://doi.org/10.3389/fped.2020.00270
  23. Ozkan H, Celebi S, Koksal N, et al. Risk factors for respiratory syncytial virus infections in moderate/late premature infants in Turkey: a prospective multicenter epidemiological study. Am J Perinatol 2021; 38: 1540-1546. https://doi.org/10.1055/s-0040-1713928
  24. Orgun A, Çetin İİ, Gürsu HA. Does prophylaxis against respiratory syncytial virus infection affect the weight percentiles of infants with hemodynamically significant congenital heart disease? Journal of Behçet Uz Children’s Hospital 2021; 11: 174-180. https://doi.org/10.5222/buchd.2021.60320
  25. Tavsu I, Gursoy T, Dirman S, Erbil N, Ovali F. Palivizumab prophylaxis: does it have any influence on the growth and development of the infants? Am J Perinatol 2014; 31: 667-672. https://doi.org/10.1055/s-0033-1356485
  26. Chen JJ, Chan P, Paes B, et al. Serious adverse events in the Canadian Registry of Children Receiving Palivizumab (CARESS) for respiratory syncytial virus prevention. PLoS One 2015; 10: e0134711. https://doi.org/10.1371/journal.pone.0134711